L D Jacobs
Overview
Explore the profile of L D Jacobs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maxion-Bergemann S, Huppertz E, Jacobs L, Muller E, Walleser S
Int J Clin Pharmacol Ther
. 2005 Jun;
43(6):271-81.
PMID: 15968884
Objective: The purpose of this study was to compare the effect of insulin glargine (glargine) and NPH insulin (NPH) on long-term outcomes in type 2 diabetes patients using the Diabetes...
2.
Weinstock-Guttman B, Jacobs L, Brownscheidle C, Baier M, Rea D, Apatoff B, et al.
Mult Scler
. 2003 Jun;
9(3):293-8.
PMID: 12814178
The objective of this study was to determine the clinical characteristics of multiple sclerosis (MS) in African American (AA) patients in the New York State Multiple Sclerosis Consortium (NYSMSC) patient...
3.
Rudick R, Goodkin D, Jacobs L, Cookfair D, Herndon R, Richert J, et al.
Neurology
. 2002 Mar;
57(12 Suppl 5):S25-30.
PMID: 11902591
No abstract available.
4.
Schwid S, Goodman A, Apatoff B, Coyle P, Jacobs L, Krupp L, et al.
Neurology
. 2001 Jan;
55(12):1901-3.
PMID: 11134392
The authors used data collected prospectively during a multicenter trial in 133 patients with secondary progressive MS to assess the relative sensitivity of quantitative functional tests and traditional measures, including...
5.
Fischer J, Priore R, Jacobs L, Cookfair D, Rudick R, Herndon R, et al.
Ann Neurol
. 2000 Dec;
48(6):885-92.
PMID: 11117545
Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon beta-1a (IFNbeta-1a, 30 microg...
6.
Jacobs L, Beck R, Simon J, Kinkel R, Brownscheidle C, Murray T, et al.
N Engl J Med
. 2000 Sep;
343(13):898-904.
PMID: 11006365
Background: Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical...
7.
Simon J, Lull J, Jacobs L, Rudick R, Cookfair D, Herndon R, et al.
Neurology
. 2000 Jul;
55(2):185-92.
PMID: 10908888
Background: T1 hypointense lesions (T1 black holes) are focal areas of relatively severe CNS tissue damage detected by MRI in patients with MS. Objective: To determine the natural history of...
8.
Nguyen L, Ramanathan M, Weinstock-Guttman B, Dole K, Miller C, Planter M, et al.
Drug Metab Dispos
. 2000 Jul;
28(8):987-93.
PMID: 10901711
The purpose of this study was to determine whether the expression of cytochrome P450 (CYP) enzyme mRNAs, other drug-metabolizing enzyme mRNAs, and transporter mRNAs can be detected using DNA arrays....
9.
Weinstock-Guttman B, Jacobs L
Drugs
. 2000 Apr;
59(3):401-10.
PMID: 10776827
Multiple sclerosis (MS) is considered an autoimmune disease associated with immune activity directed against central nervous system antigens. Based on this concept, immunosuppression and immunomodualtion have been the mainstays of...
10.
Faaij R, van Gerven J, Jolivet-Landreau I, Masclee A, Vendrig E, Schoemaker R, et al.
Aliment Pharmacol Ther
. 1999 Dec;
13(12):1605-10.
PMID: 10594395
Aim: To compare the onset of action of the local antacid Maalox and the systemic H2-antagonist ranitidine, during 'on demand' ambulant treatment of a single heartburn episode, using a randomized,...